ArticleJournal of inflammation research2026
Melatonin Suppresses NLRP3 Inflammasome Activation via SIRT1-Mediated ETS1 Deacetylation to Attenuate LPS-Induced Pyroptosis in Alveolar Epithelial Cells.
Article in Journal of inflammation research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: While melatonin is known to suppress pyroptosis in various cell types, its role and mechanisms in alveolar epithelial cells are not fully understood. Using lipopolysaccharide (LPS)-treated human pulmonary alveolar epithelial cells (HPAEpiC) as an in vitro model, this study aimed to investigate the anti-pyroptotic mechanism of melatonin. Methods: HPAEpiC cells were treated with LPS to induce pyroptosis. Cell death was assessed by propidium iodide staining, and morphological changes were examined using transmission electron microscopy (TEM). Pyroptosis-related markers were analyzed by Western blot and immunofluorescence, while inflammatory factors were measured by enzyme-linked immunosorbent assay (ELISA). Chromatin immunoprecipitation (ChIP) assay and siRNA knockdown were performed to identify key targets and mechanisms involved in melatonin-mediated inhibition of pyroptosis. Results: Melatonin significantly reduced LPS-induced pyroptosis in HPAEpiC cells. It downregulated the expression of E26 oncogene homolog 1 (ETS1), and overexpression of ETS1 reversed the anti-pyroptotic effect of melatonin. ChIP assays confirmed that ETS1 binds to the NLRP3 promoter, an interaction inhibited by melatonin. Additionally, melatonin upregulated sirtuin 1 (SIRT1), leading to ETS1 deacetylation. Knockdown of SIRT1 abolished the protective effect of melatonin against pyroptosis. Furthermore, siRNA targeting melatonin receptor 2 (MT2) attenuated melatonin-induced SIRT1 upregulation, ETS1 deacetylation, and pyroptosis inhibition. Conclusion: Our findings indicate that melatonin alleviates LPS-induced pyroptosis in alveolar epithelial cells through the MT2/SIRT1/ETS1/NLRP3 signaling pathway.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.